drugset / Trial / NCT01110785

Simvastatin and Panitumumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT01110785

Phase 2 Unknown 46 enrolled Leiden University Medical Center
Open-labelTreatment

Summary

RATIONALE: Simvastatin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving simvastatin together with panitumumab may kill more tumor cells. PURPOSE: This phase II trial is studying how well simvastatin given together with panitumumab works in treating patients with advanced or metastatic colorectal cancer.

Timeline

Start
2010-04
Primary completion
2012-04
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Panitumumab Monoclonal antibody Intravenous
Subject Simvastatin Small molecule Oral

Indications